Schreiber W, Lauer C J, Krumrey K, Holsboer F, Krieg J C
Department of Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Neuropsychopharmacology. 1996 Jul;15(1):7-15. doi: 10.1016/0893-133X(95)00146-5.
The responsiveness of the hypothalamic-pituitary-adrenocortical (HPA) system was investigated with the combined dexamethasone-corticotropin-releasing hormone (DEX-CRH) challenge test in 13 patients with "pure" panic disorder. After DEX pretreatment, this group of patients had higher CRH-induced adrenocorticotrophic hormone (ACTH) and cortisol levels than the control group, but lower than a reference group of depressed patients. The panic disorder patients were also in a middle position in the ratio of suppressors to nonsuppressors on the dexamethasone suppression test (DST) and in the ratio of normal to abnormal results on the DEX-CRH test. Our results using the combined DEX-CRH test, which is known to be much more sensitive than the original DST, support the hypothesis that HPA system functioning is altered in panic disorder patients and that this dysregulation is directly involved in the pathogenesis of the disorder.
采用联合地塞米松 - 促肾上腺皮质激素释放激素(DEX - CRH)激发试验,对13例“单纯”惊恐障碍患者的下丘脑 - 垂体 - 肾上腺皮质(HPA)系统反应性进行了研究。地塞米松预处理后,该组患者促肾上腺皮质激素释放激素(CRH)诱导的促肾上腺皮质激素(ACTH)和皮质醇水平高于对照组,但低于抑郁症参考组。惊恐障碍患者在地塞米松抑制试验(DST)中抑制者与非抑制者的比例以及DEX - CRH试验中正常与异常结果的比例也处于中间位置。我们使用联合DEX - CRH试验(已知该试验比原始DST更敏感)的结果支持以下假设:惊恐障碍患者的HPA系统功能发生改变,并且这种调节异常直接参与了该疾病的发病机制。